Adakveo Fails to Reduce VOCs in Latest Phase 3 Trial, Novartis Says
Treatment with Adakveo (crizanlizumab) did not reduce the yearly occurrence of painful vaso-occlusive crises (VOCs) leading to a medical visit, as compared with a placebo, in people with sickle cell disease (SCD), according to preliminary data from an ongoing Phase 3 trial. The study, called STAND (NCT03814746), is…